PB Fintech Reports a 42.5% Profit Jump While IRDAI's Draft Caps Take 48% Off Its Shares

PB Fintech, the listed parent of Policybazaar and Paisabazaar, reported a 42.5% rise in second-quarter net profit to ₹192.4 crore, and its shares still closed at ₹928.10 on the BSE, down 7.19% on the day and 48% since September 23, per Inc42. September 23 is the date the insurance regulator IRDAI issued a consultation paper on insurance distribution commissions. The market is pricing a rulebook that does not yet exist, and the company's own numbers show why.

Market capitalisation is ₹42,948 crore, or $4.53 billion, against $9.07 billion in early September, per Inc42. Against the ₹192.4 crore quarterly profit, annualised to roughly ₹770 crore, the market is paying about 56 times earnings for a company whose profit is growing in the low forties. That multiple only makes sense if investors believe the profit pool itself is shrinking.

What the quarter looked like

Operating revenue rose about 35% to ₹2,177.7 crore. The core online business, meaning PolicyBazaar and Paisabazaar, brought in ₹1,336 crore, up 39.5%, while new initiatives grew 28% to ₹842 crore. Adjusted EBITDA was ₹216 crore, up 39%, at a flat 10% margin.

Q2 FY27 line	Value	Change on year
Net profit	₹192.4 crore	+42.5%
Operating revenue	₹2,177.7 crore	+35%
Advertising and promotion	₹447 crore	+59%
Core credit disbursements	₹2,791 crore	+22%

The line that matters for what follows is advertising and promotion, which grew 59%, faster than revenue. Brokerage Dolat Capital said Q2 revenue was 4.2% below its estimate and operating profit missed by 32.7%, mainly on advertising and other costs, per the same Inc42 report.

What IRDAI proposed

The regulator's paper proposes hard commission caps by product and channel, tighter expense-of-management limits, a ban on bundling insurance with loans, and clawbacks where mis-selling is confirmed, according to Business Today. For health insurance the first-year cap is 15% for institutional distributors and 20% for agents. For life savings products with a premium-paying term above 10 years it is 20% for distribution entities and 25% for agents.

Motilal Oswal Financial Services gave an example in the same report: a fresh health policy pays an agent about ₹15,000 today and would pay roughly ₹3,500 to ₹3,750 under the draft. These are proposals, not final rules, and Business Today stresses that.

What management says it can offset

The stock fell 36% on September 24 and a further 4% on September 25, when it touched an intraday low of ₹1,115.10, per Business Today. In the same report, officials indicated a potential 30% hit to core online insurance revenue in FY2028 if the rules go ahead as proposed.

The offsets named are 15% to 20% recovered through volume growth and 10% to 15% savings on a current cost base the report puts at ₹3,000 crore, or ₹300 crore to ₹450 crore. Net of volume, the revenue hit shrinks to between 10% and 15%. The cost savings equal roughly one quarter's advertising bill of ₹447 crore, and that bill is the line growing fastest.

Chairman and chief executive Yashish Dahiya said the proposals could limit the point-of-sales-person model and that the company may restructure that business if the rules are adopted as drafted, per Inc42. He said the company is waiting for final regulations and is in informal talks with the regulator about other options. He also said the rules could open non-insurance services, such as charging for claims support that Policybazaar provides free.

Business Today separately reports that the company is exploring insurance or reinsurance manufacturing at an early stage. One official told it: "We are exploring all options in terms of manufacturing, whether that be insurance or reinsurance."

Brokerages are split, and the targets are close together

1. HSBC (Hold)1100 ₹
2. Dolat Capital (Reduce)1090 ₹
3. Bernstein (Outperform)1085 ₹
4. BSE close928.1 ₹

Source: Inc42, November 2026 (targets as reported); close from the same report

HSBC rates the stock Hold with a target of ₹1,100 and cut its FY27 to FY29 earnings estimates by 2% to 4%. Dolat rates it Reduce and cut its target to ₹1,090 from ₹1,150. Bernstein rates it Outperform at ₹1,085, citing 38% year-on-year premium growth and 22% growth in core credit disbursements.

The ratings differ but the targets sit within ₹15 of each other, and all three are 17% to 19% above the close. Motilal Oswal expects the stock to underperform until final rules arrive, per Business Today, and notes management's 15% to 20% volume recovery assumption.

What would change the picture

Inc42's own report contains a discrepancy: the text gives a 52-week low of ₹926 intraday and a close of ₹928.10, while its summary line cites ₹931.50. The close is the figure we use.

Neither report says when IRDAI will publish final rules, so the final framework is the next thing to watch. Our coverage of Prosus's Navi investment showed the Competition Commission clearing money into an Indian fintech; here a different regulator is proposing to cap what a distributor can earn. Compare Delhivery's Q2 profit swing for how much a quarter's headline depends on a few lines.

The test is the final IRDAI rule. If the caps arrive near the draft's 15% and 20% first-year health figures, PB Fintech's ₹300 crore to ₹450 crore of savings and its volume recovery will have to cover a 30% revenue hit. If they soften, the 48% fall will have priced in a rule that never came.